Case Report: Pulmonary alveolar proteinosis and fibrosis associated with indium-tin-oxide exposure
Abstract
Background: Pulmonary alveolar proteinosis (PAP) is a rare respiratory disorder characterized by the excessive accumulation of surfactant material on alveolar surfaces and the dysfunction of alveolar macrophages. Indium-tin-oxide (ITO), a substance utilized in liquid crystal displays and solar panels, could be a potential cause of secondary PAP. Here, we report a rare case of interstitial lung disease in a solar panel processing worker with ITO exposure, which was pathologically confirmed as PAP and then progressed to pulmonary fibrosis.
Case presentation: A 35-year-old male was admitted with a symptom of dysponea. Chest computed tomography revealed diffuse, bilateral ground-glass opacities and interlobular septal thickening in both lungs. Transbronchial lung biopsy was PAS-positive, confirming the diagnosis of PAP. The indium levels in the patient's bronchoalveolar lavage fluid and plasma were far above the normal range. He underwent whole-lung lavage, but approximately 4 months later, he still developed progressive pulmonary fibrosis. Nintedanib showed no significant effect in slowing the decline of his lung function.
Conclusion: When a patient has a definite history of indium exposure, the diagnosis of PAP should be considered. Workers need to wear protective measures daily, as lung diseases caused by ITO exposure are associated with a poor prognosis.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.